This HTML5 document contains 307 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/pdb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/pubchem-compound/
n30http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/pubchem-substance/
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/kegg-drug/
n32http://www.rxlist.com/cgi/generic/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/drugbank/
n33http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n15http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00199/identifier/chemspider/
n14http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00199
rdf:type
n3:Drug
n3:description
Erythromycin is a macrolide antibiotic produced by Streptomyces erythreus. It inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits; binding inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.
n3:dosage
n20:271B5915-363D-11E5-9242-09173F13E4C5 n20:271B5916-363D-11E5-9242-09173F13E4C5 n20:271B5917-363D-11E5-9242-09173F13E4C5 n20:271B5918-363D-11E5-9242-09173F13E4C5 n20:271B5919-363D-11E5-9242-09173F13E4C5 n20:271B591A-363D-11E5-9242-09173F13E4C5 n20:271B591B-363D-11E5-9242-09173F13E4C5 n20:271B591C-363D-11E5-9242-09173F13E4C5 n20:271B590D-363D-11E5-9242-09173F13E4C5 n20:271B590E-363D-11E5-9242-09173F13E4C5 n20:271B590F-363D-11E5-9242-09173F13E4C5 n20:271B5910-363D-11E5-9242-09173F13E4C5 n20:271B5911-363D-11E5-9242-09173F13E4C5 n20:271B5912-363D-11E5-9242-09173F13E4C5 n20:271B5913-363D-11E5-9242-09173F13E4C5 n20:271B5914-363D-11E5-9242-09173F13E4C5 n20:271B5908-363D-11E5-9242-09173F13E4C5 n20:271B5909-363D-11E5-9242-09173F13E4C5 n20:271B590A-363D-11E5-9242-09173F13E4C5 n20:271B590B-363D-11E5-9242-09173F13E4C5 n20:271B590C-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kanazawa S, Ohkubo T, Sugawara K: The effects of grapefruit juice on the pharmacokinetics of erythromycin. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):799-803. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11294369 # Ogwal S, Xide TU: Bioavailability and stability of erythromycin delayed release tablets. Afr Health Sci. 2001 Dec;1(2):90-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12789122 # Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, Ohashi K: Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol. 2007 Jul;47(7):871-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17585116
n3:group
approved
n3:halfLife
0.8 - 3 hours
n3:indication
For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to <i>Corynebacterium diphtheriae</i>, in the treatment of infections due to <i>Corynebacterium minutissimum</i>, intestinal amebiasis caused by <i>Entamoeba histolytica</i>, acute pelvic inflammatory disease caused by <i>Neisseria gonorrhoeae</i>, skin and soft tissue infections of mild to moderate severity caused by <i>Streptococcus pyogenes</i> and <i>Staphylococcus aureus</i>, primary syphilis caused by <i>Treponema pallidum</i>, infections caused by <i>Chlamydia trachomatis</i>, nongonococcal urethritis caused by <i>Ureaplasma urealyticum</i>, and Legionnaires' disease caused by <i>Legionella pneumophila</i>.
n3:manufacturer
n4:271B58A5-363D-11E5-9242-09173F13E4C5 n4:271B58A6-363D-11E5-9242-09173F13E4C5 n4:271B58A3-363D-11E5-9242-09173F13E4C5 n4:271B58A4-363D-11E5-9242-09173F13E4C5 n4:271B58A1-363D-11E5-9242-09173F13E4C5 n4:271B58A2-363D-11E5-9242-09173F13E4C5 n4:271B58B5-363D-11E5-9242-09173F13E4C5 n4:271B58B6-363D-11E5-9242-09173F13E4C5 n4:271B58B3-363D-11E5-9242-09173F13E4C5 n4:271B58B4-363D-11E5-9242-09173F13E4C5 n4:271B58B1-363D-11E5-9242-09173F13E4C5 n4:271B58B2-363D-11E5-9242-09173F13E4C5 n4:271B58AF-363D-11E5-9242-09173F13E4C5 n4:271B58B0-363D-11E5-9242-09173F13E4C5 n4:271B58AD-363D-11E5-9242-09173F13E4C5 n4:271B58AE-363D-11E5-9242-09173F13E4C5 n4:271B58AB-363D-11E5-9242-09173F13E4C5 n4:271B58AC-363D-11E5-9242-09173F13E4C5 n4:271B58A9-363D-11E5-9242-09173F13E4C5 n4:271B58AA-363D-11E5-9242-09173F13E4C5 n4:271B58A7-363D-11E5-9242-09173F13E4C5 n4:271B58A8-363D-11E5-9242-09173F13E4C5 n4:271B58C5-363D-11E5-9242-09173F13E4C5 n4:271B58C6-363D-11E5-9242-09173F13E4C5 n4:271B58C3-363D-11E5-9242-09173F13E4C5 n4:271B58C4-363D-11E5-9242-09173F13E4C5 n4:271B58C1-363D-11E5-9242-09173F13E4C5 n4:271B58C2-363D-11E5-9242-09173F13E4C5 n4:271B58BF-363D-11E5-9242-09173F13E4C5 n4:271B58C0-363D-11E5-9242-09173F13E4C5 n4:271B58BD-363D-11E5-9242-09173F13E4C5 n4:271B58BE-363D-11E5-9242-09173F13E4C5 n4:271B58BB-363D-11E5-9242-09173F13E4C5 n4:271B58BC-363D-11E5-9242-09173F13E4C5 n4:271B58B9-363D-11E5-9242-09173F13E4C5 n4:271B58BA-363D-11E5-9242-09173F13E4C5 n4:271B58B7-363D-11E5-9242-09173F13E4C5 n4:271B58B8-363D-11E5-9242-09173F13E4C5 n4:271B58D1-363D-11E5-9242-09173F13E4C5 n4:271B58D2-363D-11E5-9242-09173F13E4C5 n4:271B58CF-363D-11E5-9242-09173F13E4C5 n4:271B58D0-363D-11E5-9242-09173F13E4C5 n4:271B58CD-363D-11E5-9242-09173F13E4C5 n4:271B58CE-363D-11E5-9242-09173F13E4C5 n4:271B58CB-363D-11E5-9242-09173F13E4C5 n4:271B58CC-363D-11E5-9242-09173F13E4C5 n4:271B58C9-363D-11E5-9242-09173F13E4C5 n4:271B58CA-363D-11E5-9242-09173F13E4C5 n4:271B58C7-363D-11E5-9242-09173F13E4C5 n4:271B58C8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n30:DB00199 n33:DB00199
dcterms:title
Erythromycin
adms:identifier
n7:Erythromycin n16:46508487 n17:PA449493 n18:12560 n19:0168-0215-01 n21:ERY n22:C01912 n23:D00140 n24:DB00199 n25:48923 n27:12041
n3:mechanismOfAction
Erythromycin acts by penetrating the bacterial cell membrane and reversibly binding to the 50 S subunit of bacterial ribosomes or near the &ldquo;P&rdquo; or donor site so that binding of tRNA (transfer RNA) to the donor site is blocked. Translocation of peptides from the &ldquo;A&rdquo; or acceptor site to the &ldquo;P&rdquo; or donor site is prevented, and subsequent protein synthesis is inhibited. Erythromycin is effective only against actively dividing organisms. The exact mechanism by which erythmromycin reduces lesions of acne vulgaris is not fully known: however, the effect appears to be due in part to the antibacterial activity of the drug.
n3:packager
n4:271B5846-363D-11E5-9242-09173F13E4C5 n4:271B5892-363D-11E5-9242-09173F13E4C5 n4:271B5886-363D-11E5-9242-09173F13E4C5 n4:271B5883-363D-11E5-9242-09173F13E4C5 n4:271B588F-363D-11E5-9242-09173F13E4C5 n4:271B5844-363D-11E5-9242-09173F13E4C5 n4:271B5890-363D-11E5-9242-09173F13E4C5 n4:271B5884-363D-11E5-9242-09173F13E4C5 n4:271B5849-363D-11E5-9242-09173F13E4C5 n4:271B5895-363D-11E5-9242-09173F13E4C5 n4:271B584A-363D-11E5-9242-09173F13E4C5 n4:271B5896-363D-11E5-9242-09173F13E4C5 n4:271B5847-363D-11E5-9242-09173F13E4C5 n4:271B5893-363D-11E5-9242-09173F13E4C5 n4:271B5848-363D-11E5-9242-09173F13E4C5 n4:271B5894-363D-11E5-9242-09173F13E4C5 n4:271B584D-363D-11E5-9242-09173F13E4C5 n4:271B584E-363D-11E5-9242-09173F13E4C5 n4:271B584B-363D-11E5-9242-09173F13E4C5 n4:271B584C-363D-11E5-9242-09173F13E4C5 n4:271B5871-363D-11E5-9242-09173F13E4C5 n4:271B5872-363D-11E5-9242-09173F13E4C5 n4:271B586F-363D-11E5-9242-09173F13E4C5 n4:271B5870-363D-11E5-9242-09173F13E4C5 n4:271B5875-363D-11E5-9242-09173F13E4C5 n4:271B5876-363D-11E5-9242-09173F13E4C5 n4:271B5873-363D-11E5-9242-09173F13E4C5 n4:271B5874-363D-11E5-9242-09173F13E4C5 n4:271B5879-363D-11E5-9242-09173F13E4C5 n4:271B587A-363D-11E5-9242-09173F13E4C5 n4:271B5877-363D-11E5-9242-09173F13E4C5 n4:271B5878-363D-11E5-9242-09173F13E4C5 n4:271B587B-363D-11E5-9242-09173F13E4C5 n4:271B5861-363D-11E5-9242-09173F13E4C5 n4:271B5862-363D-11E5-9242-09173F13E4C5 n4:271B585F-363D-11E5-9242-09173F13E4C5 n4:271B5860-363D-11E5-9242-09173F13E4C5 n4:271B5865-363D-11E5-9242-09173F13E4C5 n4:271B5866-363D-11E5-9242-09173F13E4C5 n4:271B5863-363D-11E5-9242-09173F13E4C5 n4:271B5864-363D-11E5-9242-09173F13E4C5 n4:271B5869-363D-11E5-9242-09173F13E4C5 n4:271B586A-363D-11E5-9242-09173F13E4C5 n4:271B5867-363D-11E5-9242-09173F13E4C5 n4:271B5868-363D-11E5-9242-09173F13E4C5 n4:271B586D-363D-11E5-9242-09173F13E4C5 n4:271B586E-363D-11E5-9242-09173F13E4C5 n4:271B586B-363D-11E5-9242-09173F13E4C5 n4:271B586C-363D-11E5-9242-09173F13E4C5 n4:271B5899-363D-11E5-9242-09173F13E4C5 n4:271B589A-363D-11E5-9242-09173F13E4C5 n4:271B5897-363D-11E5-9242-09173F13E4C5 n4:271B5898-363D-11E5-9242-09173F13E4C5 n4:271B5851-363D-11E5-9242-09173F13E4C5 n4:271B589D-363D-11E5-9242-09173F13E4C5 n4:271B5852-363D-11E5-9242-09173F13E4C5 n4:271B589E-363D-11E5-9242-09173F13E4C5 n4:271B584F-363D-11E5-9242-09173F13E4C5 n4:271B589B-363D-11E5-9242-09173F13E4C5 n4:271B5850-363D-11E5-9242-09173F13E4C5 n4:271B589C-363D-11E5-9242-09173F13E4C5 n4:271B5855-363D-11E5-9242-09173F13E4C5 n4:271B5856-363D-11E5-9242-09173F13E4C5 n4:271B5853-363D-11E5-9242-09173F13E4C5 n4:271B589F-363D-11E5-9242-09173F13E4C5 n4:271B5854-363D-11E5-9242-09173F13E4C5 n4:271B58A0-363D-11E5-9242-09173F13E4C5 n4:271B5859-363D-11E5-9242-09173F13E4C5 n4:271B585A-363D-11E5-9242-09173F13E4C5 n4:271B5857-363D-11E5-9242-09173F13E4C5 n4:271B5858-363D-11E5-9242-09173F13E4C5 n4:271B585D-363D-11E5-9242-09173F13E4C5 n4:271B5889-363D-11E5-9242-09173F13E4C5 n4:271B587D-363D-11E5-9242-09173F13E4C5 n4:271B585E-363D-11E5-9242-09173F13E4C5 n4:271B588A-363D-11E5-9242-09173F13E4C5 n4:271B587E-363D-11E5-9242-09173F13E4C5 n4:271B585B-363D-11E5-9242-09173F13E4C5 n4:271B5887-363D-11E5-9242-09173F13E4C5 n4:271B585C-363D-11E5-9242-09173F13E4C5 n4:271B5888-363D-11E5-9242-09173F13E4C5 n4:271B587C-363D-11E5-9242-09173F13E4C5 n4:271B5881-363D-11E5-9242-09173F13E4C5 n4:271B588D-363D-11E5-9242-09173F13E4C5 n4:271B5882-363D-11E5-9242-09173F13E4C5 n4:271B588E-363D-11E5-9242-09173F13E4C5 n4:271B587F-363D-11E5-9242-09173F13E4C5 n4:271B588B-363D-11E5-9242-09173F13E4C5 n4:271B5880-363D-11E5-9242-09173F13E4C5 n4:271B588C-363D-11E5-9242-09173F13E4C5 n4:271B5845-363D-11E5-9242-09173F13E4C5 n4:271B5891-363D-11E5-9242-09173F13E4C5 n4:271B5885-363D-11E5-9242-09173F13E4C5
n3:synonym
Erythromycinum Erythromycin Erythromycin C Abomacetin (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione Eritromicina 3''-O-demethylerythromycin Erythromycin A Erythromycine
n3:toxicity
Symptoms of overdose include diarrhea, nausea, stomach cramps, and vomiting.
n8:hasAHFSCode
n9:52-04-04 n9:08-12-12-04 n9:34-00-00
n3:foodInteraction
Take on empty stomach: 1 hour before or 2 hours after meals. Take with a full glass of water Avoid taking with grapefruit juice. Avoid alcohol.
n3:mixture
n26:271B5842-363D-11E5-9242-09173F13E4C5 n26:271B5843-363D-11E5-9242-09173F13E4C5 n26:271B5840-363D-11E5-9242-09173F13E4C5 n26:271B5841-363D-11E5-9242-09173F13E4C5 n26:271B583E-363D-11E5-9242-09173F13E4C5 n26:271B583F-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Erythromycin is largely bound to plasma proteins, ranging from 75 - 95% binding depending on the form.
n3:synthesisReference
Takehiro Amano, Masami Goi, Kazuto Sekiuchi, Tomomichi Yoshida, Masahiro Hasegawa, "Process for preparing erythromycin A oxime or a salt thereof." U.S. Patent US5274085, issued October, 1966.
n12:hasConcept
n13:M0007715
foaf:page
n11:erythromycin-ointment.html n15:ery1163.shtml n32:erithrom.htm
n3:IUPAC-Name
n5:271B5921-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5927-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5926-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5923-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5924-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5925-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5937-363D-11E5-9242-09173F13E4C5 n5:271B591F-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5939-363D-11E5-9242-09173F13E4C5 n5:271B5920-363D-11E5-9242-09173F13E4C5 n5:271B591D-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B591E-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B593B-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n14:D10AF02 n14:J01FA01 n14:S01AA17
n3:H-Bond-Acceptor-Count
n5:271B592D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B592E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5928-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5929-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B592B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B592A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B592C-363D-11E5-9242-09173F13E4C5
n3:absorption
Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Topical application of the ophthalmic ointment to the eye may result in absorption into the cornea and aqueous humor.
n3:affectedOrganism
Staphylococcus aureus Enteric bacteria and other eubacteria Streptococcus pyogenes Haemophilus influenzae
n3:caco2-Permeability
n5:271B593A-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
114-07-8
n3:category
n3:containedIn
n28:271B58FC-363D-11E5-9242-09173F13E4C5 n28:271B58FD-363D-11E5-9242-09173F13E4C5 n28:271B58FA-363D-11E5-9242-09173F13E4C5 n28:271B58FB-363D-11E5-9242-09173F13E4C5 n28:271B5900-363D-11E5-9242-09173F13E4C5 n28:271B5901-363D-11E5-9242-09173F13E4C5 n28:271B58FE-363D-11E5-9242-09173F13E4C5 n28:271B58FF-363D-11E5-9242-09173F13E4C5 n28:271B5904-363D-11E5-9242-09173F13E4C5 n28:271B5905-363D-11E5-9242-09173F13E4C5 n28:271B5902-363D-11E5-9242-09173F13E4C5 n28:271B5903-363D-11E5-9242-09173F13E4C5 n28:271B5906-363D-11E5-9242-09173F13E4C5 n28:271B5907-363D-11E5-9242-09173F13E4C5 n28:271B58F5-363D-11E5-9242-09173F13E4C5 n28:271B58D5-363D-11E5-9242-09173F13E4C5 n28:271B58F6-363D-11E5-9242-09173F13E4C5 n28:271B58D6-363D-11E5-9242-09173F13E4C5 n28:271B58F3-363D-11E5-9242-09173F13E4C5 n28:271B58D3-363D-11E5-9242-09173F13E4C5 n28:271B58F4-363D-11E5-9242-09173F13E4C5 n28:271B58D4-363D-11E5-9242-09173F13E4C5 n28:271B58D9-363D-11E5-9242-09173F13E4C5 n28:271B58DA-363D-11E5-9242-09173F13E4C5 n28:271B58D7-363D-11E5-9242-09173F13E4C5 n28:271B58D8-363D-11E5-9242-09173F13E4C5 n28:271B58F8-363D-11E5-9242-09173F13E4C5 n28:271B58F9-363D-11E5-9242-09173F13E4C5 n28:271B58DB-363D-11E5-9242-09173F13E4C5 n28:271B58F7-363D-11E5-9242-09173F13E4C5 n28:271B58E5-363D-11E5-9242-09173F13E4C5 n28:271B58E6-363D-11E5-9242-09173F13E4C5 n28:271B58E3-363D-11E5-9242-09173F13E4C5 n28:271B58E4-363D-11E5-9242-09173F13E4C5 n28:271B58E9-363D-11E5-9242-09173F13E4C5 n28:271B58EA-363D-11E5-9242-09173F13E4C5 n28:271B58E7-363D-11E5-9242-09173F13E4C5 n28:271B58E8-363D-11E5-9242-09173F13E4C5 n28:271B58ED-363D-11E5-9242-09173F13E4C5 n28:271B58EE-363D-11E5-9242-09173F13E4C5 n28:271B58EB-363D-11E5-9242-09173F13E4C5 n28:271B58EC-363D-11E5-9242-09173F13E4C5 n28:271B58F1-363D-11E5-9242-09173F13E4C5 n28:271B58F2-363D-11E5-9242-09173F13E4C5 n28:271B58EF-363D-11E5-9242-09173F13E4C5 n28:271B58F0-363D-11E5-9242-09173F13E4C5 n28:271B58DD-363D-11E5-9242-09173F13E4C5 n28:271B58DE-363D-11E5-9242-09173F13E4C5 n28:271B58DC-363D-11E5-9242-09173F13E4C5 n28:271B58E1-363D-11E5-9242-09173F13E4C5 n28:271B58E2-363D-11E5-9242-09173F13E4C5 n28:271B58DF-363D-11E5-9242-09173F13E4C5 n28:271B58E0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5933-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5935-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5936-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5938-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5932-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5931-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5934-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5922-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B592F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5930-363D-11E5-9242-09173F13E4C5